Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 860

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 860
---
(7,245) Loss on lease termination  1,384   - Impairment on investments in equity securities  -   6,194 Impairment on property  40,173   - Property, plant and equipment written off  -   18 Stock written off  -   424 Operating loss before working capital changes  (2,349,658)  (1,940,191)         Changes in operating assets and liabilities:        Inventories  (250,854)  (160,387)Trade and other receivables  147,760   650,810 Trade and other payables  204,342   (381,293)Advance payment from customer  95,879   (23,123)Operating lease liabilities  (42,895)  76,620 Tax (liabilities)/recoverable  (38,834)  (44,648)Net cash used in operating activities  (2,234,260)  (1,822,212)         Cash flows from investing activities:        Acquisition of investments in equity securities  (492,732)  (320,733)Dividend income  68,130   61,409 Change in fixed deposits placed with original maturities more than three months  (78,835)  (1,411,626)Purchase of plant and equipment  (226,989)  (149,398)Proceeds from disposal of investments in equity securities  1,068,777   26,146 Proceeds from settlement of supplier contract dispute  79,851   - Net cash generated from/(used in) investing activities  418,202   (1,794,202)

 F-8Table of Contents

BIONEXUS GENE LAB CORP.CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023(Currency expressed in United States Dollars (“US$”))(CONT’D)(Audited) 

Cash flows from financing activities:      Advances from directors  3,975   13,199 Share-based compensation        141,000   511,740 Shares subscriptions  -   5,